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INTRODUCTION
In March 1996 the discovery of a new form of 
Creutzfeldt-Jakob disease (CJD) was 
announced to a shocked world. In order to 
understand why this news took the headlines 
by storm, it is necessary to trace the history of 
this rare disease and in particular its links with 
bovine spongiform encephalopathy (BSE), or 
“mad cow disease”. By 1996, Britain had been 
in the throes of the BSE epidemic for ten years 
and it was believed that cows had contracted 
the disease by consumption of scrapie- 
contaminated food-stuff, scrapie being a 
similar but much older disease in sheep. 
Because this represented a species jump from 
sheep to cows, it was predicted in many 
quarters that BSE posed a new threat to human 
health. Therefore the Government took steps 
to remove BSE contaminated products from 
the human food chain and the Department of 
Health set up a surveillance programme to 
monitor the incidence of CJD in UK. 
Although CJD occurred subsequently in 
several British farmers who had BSE amongst 
their herds, the numbers were not significant 
and there was no rise in the incidence of CJD 
in UK above what might have been expected 
from heightened awareness of the disease and 
better ascertainment of cases. The 
Government continued to reassure the public 
about the safety of British beef but unease
remained widespread and the question of CJD 
and BSE was never far from the headlines. It 
was against this background that the sudden 
appearance in UK of what appeared to be a 
new form of CJD in 10 young people caused 
major panic1. Immediately, the new variant of 
CJD (nvCJD) was linked in the press with 
BSE. In fact, there do appear to be some 
scientific grounds for concluding that nvCJD 
does results from transmission of BSE, which 
carries the implication that because huge 
numbers of people have been exposed to a 
similar risk, thousands of people may be 
smitten by this new plague. So what do we 
know about CJD which might help to 
determine the likely future outcome? In fact, 
the story has all the elements of a fascinating 
scientific thriller - a very rare disease with a 
long and silent incubation period, a disease 
both genetic and transmissible, caused by a 
unique and elusive agent which is apparently 
capable of replicating itself in the absence of 
nucleic acid2.
CJD IS TRANSMISSIBLE
First described in the 1920s by Creutzfeldt and 
then Jakob, in a handful of patients (most of
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w hom  turned out subsequently  not to have 
C JD !), the clinical phenotype o f  C JD  was soon 
defined in term s o f  a rapid ly  progressive  and 
fatal dem entia. It becam e clear that the 
neuropatho logy  o f  th is condition resem bled 
that o f scrapie, a disease  o f sheep that had been 
know n for 200 years. Both w ere characterised  
by a trophy  o f the brain (F ig  1), m icroscopic 
vacuolation  o f the grey m atter with 
accom panying  neuronal loss and g liosis (Fig 2) 
and, in som e cases, am yloid plaques. The 
hum an and anim al d iseases w ere linked under 
the term , spongiform  encephalopath ies. In the 
1950s, suspicion  began to grow  that these 
d iseases m ight be transm issib le, especially  
with the d iscovery  o f  a sim ilar disease called 
kuru, in a rem ote  tribe inhab iting  Papua New 
G uinea, w ho practiced  cannibalistic  funeral 
ritua ls3. T his prom pted som e crucial 
experim ents in w hich affected brain tissue was 
inoculated  into an im als and the transm issib ility  
was confirm ed  when the recip ien ts developed 
spongiform  encephalopathy  after a 
com paratively  long incubation  period. In kuru 
a lso there was often a delay  o f  years betw een 
ingestion o f the infected m aterial and the onset 
o f  sym ptom s. O nce the tribe w ere persuaded 
to abandon their particular funeral practices, 
kuru becam e far less com m on and has now 
virtually  d isappeared  a lthough one or two 
cases are  still occurring , h igh ligh ting  the fact 
that the incubation period m ay be as long as 
forty  years.
K uru was the first know n exam ple o f  hum an to 
hum an transm ission o f a spongiform  
encephalopathy. E xperim ental ev idence from  
inoculation  o f affected hum an brain tissue into
Fig. 1 C oronal section  o f  brain from  a patien t w ith CJD  
show ing a ty rophy  and ven tricu lar dilatation.
anim als show ed that hum an to  anim al 
transm ission  could  a lso  occur. If  further 
ev idence was needed that these d iseases w ere 
transm issib le, the occurrence  o f  iatrogenic 
C JD  in the course  o f  m edical and surgical 
treatm ents certain ly  confirm ed  the risk. 
Iatrogenic transm ission  o f C JD  has been 
reported  occasionally  fo llow ing  neurosurgical 
p rocedures and in patien ts rece iv ing  corneal or 
dural transplants, but m ore often in young 
patients w ho w ere treated  with cadaver-
Fig.2 S ection  o f  the cerebral cortex  from  a patien t with 
C JD  show ing vacuolation  o f  the  grey matter. 
H aem atoxylin  and easin x200.
derived hum an grow th horm one prior to the 
1980s4, som e o f w hom  later developed CJD. 
Sym ptom s o f C JD  w ere m anifested  in the 
recip ien ts betw een tw o and  thirty  years after 
the therapeu tic  procedure.
CJD IS GENETIC
W hile all this ev idence  ind icated  that the 
spongiform  encephalopath ies were
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transm issib le  diseases, it was also becom ing 
c lear that in som e cases there was a  significant 
genetic  com ponent5. A lthough around 85%  of 
C JD  cases occur sporadically  and in isolation, 
the rem ainder have a history of o ther affected 
fam ily m em bers. An even rarer form of 
hum an spongiform  encephalopathy known as 
the G erstm ann-S traussler-Scheinker syndrom e 
(GSS) occurred only in several very large 
k indreds and the disease was clearly  inherited. 
Fatal fam ilial insom nia is a m ore recently 
recognised m em ber o f this group of heritable 
C JD -like d iseases, but does not display 
spongiform  change, rendering  the term  
spongiform  encephalopathy no longer 
appropriate.
GENETIC AND TRANSM ISSIBLE - What 
is the infective agent?
T he fact that these d iseases could be both 
transm issib le and inherited m ade them  of 
unique interest and focused attention on 
characterising  the infective agent in the hum an 
diseases. Parallel studies o f scrapie were in 
progress both to isolate the infective agent and 
to identify the  genetic  background6. The 
genetic  locus was identified and nam ed in 
E d inburgh’s N europathogenesis Unit as the sip 
gene in sheep and the sinc gene in mice. 
Inoculation experim ents in which scrapie brain 
m aterial was injected into m ice dem onstrated a 
range o f incubation periods and pathology 
patterns w hich were very reproducible and 
w hich w ere attributed  to strain variations of 
the infective agen t7. T his was thought at first to 
be a “slow ” virus (slow  because o f the long 
incubation period). H ow ever despite intensive 
study, no nucleic acid was ever identified in 
the infective m aterial used for transm ission 
experim ents, leading to the concept o f a virino,
this being a very sm all particle  o f nucleic acid 
w hich was coated with a protein derived from 
the host anim al. W hile som e w orkers still 
entertain  this concept, current thinking on the 
nature o f the infective agent has sw ung in 
favour o f the "protein only” hypothesis which 
has been strongly advocated by P rusiner2. In 
this m odel, the infective agent is m ade up of 
protein (which Prusiner has nam ed prion 
protein, a term  constructed  from  proteinaceous 
infective particle). Prion protein, at least in the 
form  which accum ulates in d iseased brains
Fig.3 Im m unohistoche m ical evidence o f  PrP deposition in 
relation to vacuolation  o f  the cortex in a case o f  CJD  x400.
(Fig 3), is an insoluble, protease resistant 
protein which is form ed by pathological 
conversion o f a norm al cell surface protein 
present in all brains and chiefly  on the surfaces 
o f  neurones. T his protein is o f  unknown 
function and is coded from  a gene, the PrP 
gene, which is located on chrom osom e 
20 . W ork in the last decade has revealed that 
fam ilial cases o f C JD , fatal fam ilial insom nia 
and all cases o f  G SS, are associated with 
m utations in the PrP  gene. It also appears that 
the allelic  m ake up of codon 129 of the PrP 
gene is peculiarly  influential in that 
hom ozygosity  for valine or m ethionine at this 
locus confers susceptib ility  to the disease both 
in sporadic and in acquired  CJD. To 
sum m arise  the prion theory briefly, the notion 
is that in affected indiv iduals the norm al 
soluble form  o f PrP  undergoes a post-
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translational modification to an insoluble form 
which is deposited in different patterns and 
locations in the central nervous system (Fig 3), 
giving rise to the characteristic pathology and 
symptomatic disease. The possession of a PrP 
mutation makes this change very much more 
likely to occur so that mutation-bearing 
individuals have a strong likelihood of 
developing disease in their lifetime. Cases of 
sporadic CJD are attributed to spontaneous 
post-translational modification occurring in the 
brain of that individual for unknown reasons. 
In iatrogenic cases, the infective protein may 
have been introduced directly in contact with 
the brain (e.g. by dural transplant) and this 
initiates a relatively rapid onset of translational 
modification of the host PrP. In patients 
inoculated peripherally (e.g. injections of 
infected growth hormone) the agent 
presumably travels from the periphery to the 
brain where the pathogenetic change 
commences somewhat later. The route by 
which the agent travels from the periphery to 
the brain is still unknown but may be along 
peripheral nerves and through the spinal cord, 
or through lymphatics and involving the 
lymphoid tissues and the spleen, or by the 
bloodstream.
Although there is persuasive evidence for the 
protein-only hypothesis particularly from the 
spontaneous development of disease in 
transgenic animals bearing a mutated human 
PrP gene, there are still some unexplained 
features such as strain variation7, which 
suggest that other factors may play a part in 
transmissibility. Many workers in the field 
consider that variations in pathology and 
incubation period are governed solely by the 
host genome which controls expression of the 
PrP gene and that extraneous nucleic acid is
not required to explain the phenomena of 
transmission. So far as function of the normal 
prion is concerned, it is o f interest to note that 
animals in whom the PrP gene has been 
deleted progress to old age in an apparently 
normal manner without neurological deficits. 
These PrP-null animals also fail to develop any 
signs of disease when inoculated with infective 
material, confirming that the presence of 
normal host protein is required as a basis for 
subversion in the disease state. W hatever the 
true function of normal PrP proves to be, it is 
widely expressed in many different tissues and 
it is somewhat perplexing that pathology and 
symptoms are confined to the nervous system.
It should be emphasised that the disease is not 
contagious in the sense o f being transmitted by 
normal contact with affected individuals but 
requires inoculation or ingestion of infected 
material to effect transmission.
DECONTAMINATION OF PRION 
PROTEIN
In addition to eluding exact identification, the 
transmissible agent displays some unique 
properties in resisting many o f the usual 
decontaminating agents such as boiling water, 
ultraviolet radiation, alcohol, nucleases and 
even formalin fixation and gluteraldehyde. 
Subsequent experiments have confirmed that 
the agent is rem arkably persistent in the 
environment and can remain infective after 
years in the soil. The only measures which are 
thought to be effective in degrading infectivity 
include very strong chlorine solutions, strong 
sodium hydroxide, formic acid, prolonged 
autoclaving at high tem perature and 
incineration. The rem arkably resistant and 
persistent properties of the agent only add to 
its mystique and cause enormous problems in
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planning for effective removal from the 
environment or destruction of infected 
material.
BSE AND HUMAN HEALTH
The appearance of the new cattle disease, BSE, 
led to the Department of Health asking Dr. R. 
Will, who had previous experience of this task, 
to set up a surveillance project for CJD in the 
UK8. This was established in Edinburgh in 
1990 and the neuropathological arm of this 
surveillance project was instituted by the 
author to confirm the diagnosis of CJD in 
clinically ascertained cases. Dr J Ironside 
joined the project shortly after it was initiated. 
The CJD Surveillance Unit monitored all cases 
of suspect CJD in the UK from 1990 onwards 
and sought to identify the risk factors for 
development of sporadic disease by 
comparison with suitable controls. A high 
autopsy rate was maintained and this allowed 
validation of the clinical diagnosis. 
Approximately 40-50 cases of sporadic CJD 
were identified in UK per annum until 1995 
when a number of unusually young patients 
were referred to the Unit with a diagnosis of 
suspected CJD. These patients had an atypical 
clinical presentation with a psychiatric onset 
followed by progressive ataxia and finally 
cognitive impairment. As the pathology 
became available through biopsy and then 
autopsy of these young patients, it became 
clear that they did indeed display some 
features of CJD but with a highly unusual 
pattern of prion deposition which was 
remarkably uniform between cases. These 
features included the very widespread 
appearance of prion amyloid plaques in the 
cerebral cortex and particularly heavy deposits 
of prion protein in the cerebellum. By
February 1996, 10 young cases of CJD had 
been identified with this apparently new 
pattern of pathology. None of them showed a 
PrP mutation or had a history suggestive of 
iatrogenic transmission. They were however 
all methionine homozygous at codon 129 of 
the prion gene. Review of previous young 
cases that had happened occasionally in the 
past and consultation with European 
colleagues involved in similar surveillance 
projects revealed that this cluster of young 
cases was peculiar to the UK and that the 
pathology was of a pattern not previously 
described. Subsequently one similar case has 
been described in France. This group of young 
CJD patients was announced in Parliament in 
March 1996 and published in the Lancet in 
April 19961. It was widely assumed that this 
new variant CJD represented the transmission 
of BSE to humans and the description of 
similar pathology produced in macaque 
monkey brains by inoculation of BSE material 
only strengthened this hypothesis. Since 
publication of the initial 10 cases, a further 
seven cases have occurred in UK but nowhere 
else in the world. In view of what is known of 
the incubation period of these diseases, it is 
impossible to predict how many cases of 
nvCJD will occur in the future particularly in 
human hosts of different PrP genotype. 
Ongoing surveillance of CJD in UK will be 
required for at least the next decade. 
Meanwhile the efforts to eradicate BSE from 
British herds continues and there is no 
optimism that this will be easy considering 
what is known of the persistent and resistant 
nature of the infective agent. Research work is 
still in progress to establish or refute the 
connection between BSE and nvCJD and to 
determine the route by which the infective 
agent reaches the central nervous system. The
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need to develop a clinical test for CJD remains 
param ount and the recent description of 
detection of PrP in tonsilar tissue is of great 
interest both from a diagnostic and 
pathogenetic viewpoint9.
If  it is proven that nvCJD is due to the 
transmission o f CJD, the cost to families who 
have lost young people to a dread disease, and 
the cost to the Government o f millions of 
animals slaughtered, lost export markets and 
lost public confidence has been incalculable. 
It is a sign of the potency of public concern 
and condemnation that millions of pounds 
have now been directed to research in this 
field. Let us hope that this unique group of 
diseases with their underlying fascinating 
scientific conundrum remain very rare in the 
human population.
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Comment:
Clinical Features
The clinical features o f nvCJD are relatively 
distinct from those o f the sporadic form of 
CJD, however, there is som e overlap in the 
presenting symptoms and disease course: the 
absolute diagnosis is confirmed only by 
neuropathological tests.
The earliest clinical features o f nvCJD occur at 
a mean age of 29 years. The median duration 
o f the illness is longer than that o f sporadic 
CJD (14 months for nvCJD compared to 4.5 
months). Over this period the most prom inent 
features are the psychiatric disturbances or 
sensory symptoms or both 1 . The sensory 
symptoms reported include foot pain, 
paraesthesia in the legs and persistently cold 
feet. Most cases where psychiatric diagnoses 
were suggested were depressed, apathetic and 
withdrawn. These initial neurological 
symptoms are followed by m ore gross 
neurological dysfunction, m ostly ataxia and a 
rapidly progressive dem entia with involuntary 
limb movements, urinary incontinence and 
immobility.
These patients are dependent on continuous 
nursing care and the developm ent o f aphagia 
may indicate the need for I.V. fluids and 
artificial feeding. Before death patients are 
increasingly unresponsive, akinetic and mute.
1. Z e ider M et al. 1997 T he L ancet 3 50 : 903-907.
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